JP2015532425A5 - - Google Patents

Download PDF

Info

Publication number
JP2015532425A5
JP2015532425A5 JP2015535153A JP2015535153A JP2015532425A5 JP 2015532425 A5 JP2015532425 A5 JP 2015532425A5 JP 2015535153 A JP2015535153 A JP 2015535153A JP 2015535153 A JP2015535153 A JP 2015535153A JP 2015532425 A5 JP2015532425 A5 JP 2015532425A5
Authority
JP
Japan
Prior art keywords
subject
marker
mucosal healing
markers
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015535153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/059077 external-priority patent/WO2014054013A1/en
Publication of JP2015532425A publication Critical patent/JP2015532425A/ja
Publication of JP2015532425A5 publication Critical patent/JP2015532425A5/ja
Pending legal-status Critical Current

Links

JP2015535153A 2012-10-05 2013-10-02 粘膜治癒を予測及びモニタリングするための方法 Pending JP2015532425A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261710491P 2012-10-05 2012-10-05
US61/710,491 2012-10-05
US201361824959P 2013-05-17 2013-05-17
US61/824,959 2013-05-17
PCT/IB2013/059077 WO2014054013A1 (en) 2012-10-05 2013-10-02 Methods for predicting and monitoring mucosal healing

Publications (2)

Publication Number Publication Date
JP2015532425A JP2015532425A (ja) 2015-11-09
JP2015532425A5 true JP2015532425A5 (enExample) 2016-11-24

Family

ID=49447587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535153A Pending JP2015532425A (ja) 2012-10-05 2013-10-02 粘膜治癒を予測及びモニタリングするための方法

Country Status (11)

Country Link
US (1) US20150355195A1 (enExample)
EP (3) EP3217179B9 (enExample)
JP (1) JP2015532425A (enExample)
CN (1) CN104838270A (enExample)
AU (2) AU2013326070A1 (enExample)
CA (1) CA2887035A1 (enExample)
ES (2) ES2638971T3 (enExample)
HK (1) HK1213051A1 (enExample)
MX (1) MX358730B (enExample)
SG (1) SG11201502646RA (enExample)
WO (1) WO2014054013A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
EP3210027B1 (en) * 2014-10-20 2019-04-17 Nestec S.A. Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
WO2016066174A1 (en) 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing
GB201501612D0 (en) * 2015-01-30 2015-03-18 Univ Birmingham Assay
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CN111094984A (zh) 2017-05-31 2020-05-01 普罗米修斯生物科学公司 克罗恩氏病患者的粘膜愈合评估方法
CN110646620A (zh) * 2019-09-29 2020-01-03 湖北新纵科病毒疾病工程技术有限公司 一种同时检测四项炎症标志物的方法及其试剂盒
CN111477325A (zh) * 2020-04-09 2020-07-31 赣南师范大学 基于粒子群优化算法对引发肠道溃疡疾病进行鉴别的方法
CN120600283A (zh) * 2025-05-29 2025-09-05 北京大学第三医院(北京大学第三临床医学院) 一种基于临床知识图谱的中医生殖内分泌疾病诊断辅助系统

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0615129T3 (da) 1993-03-10 2000-08-07 Cedars Sinai Medical Center Fremgangsmåder til selektiv påvisning af perinukleært anti-neutrophilt cytoplasmatisk antistof fra ulcerativ colitis eller
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
AU2001253746A1 (en) * 2000-04-20 2001-11-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Inducible plasmid vector encoding tgf-beta and uses thereof
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
EP1687447A4 (en) 2003-11-03 2008-04-02 Univ Duke METHOD FOR IDENTIFYING INDIVIDUALS IN THE HAZARD OF PERIOPERATIVE BLOODING, A KIDNEY PROBLEM OR A STROKE
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US7868139B2 (en) 2006-01-24 2011-01-11 Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
RU2442171C2 (ru) 2006-09-21 2012-02-10 Промитьюс Лабораториз Инк. Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках
AU2008276251B2 (en) 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
EP2602623B1 (en) 2008-02-25 2015-09-16 Nestec S.A. Mehtod for the detection of intracellular truncated receptors
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
EP2430443B1 (en) 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
CA2777934A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
AU2010324735A1 (en) * 2009-11-25 2012-07-12 Nestec S.A. Novel genomic biomarkers for irritable bowel syndrome diagnosis
MX2012014096A (es) * 2010-06-04 2013-04-19 Nestec Sa Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
AU2011317149B2 (en) 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
SG10201510086VA (en) 2010-12-23 2016-01-28 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
SG192770A1 (en) 2011-02-17 2013-09-30 Nestec Sa Assays for detecting autoantibodies to anti-tnfalpha drugs
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링

Similar Documents

Publication Publication Date Title
JP2015532425A5 (enExample)
Taylor‐Weiner et al. A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH
Kazankov et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C
Luo et al. Gene expression signatures associated with survival times of pediatric patients with biliary atresia identify potential therapeutic agents
Yugawa et al. Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma
JP2014519018A5 (enExample)
JP2015502740A5 (enExample)
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
Zhang et al. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy
Basili et al. Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: the ARAPACIS Study
CN107208141A (zh) 用于结直肠癌相关疾病的生物标志物
Mao et al. A low neutrophil to lymphocyte ratio before preoperative chemotherapy predicts good outcomes after the resection of colorectal liver metastases
WO2019033444A1 (zh) 乙肝肝脏疾病t淋巴细胞免疫状态应用性评估模型的构建方法
Åström et al. Telomere length and physical performance among older people—the Helsinki birth cohort study
Zhu et al. Left atrial appendage circular RNAs are new predictors of atrial fibrillation recurrence after surgical ablation in valvular atrial fibrillation patients
Barreiro et al. Update in chronic obstructive pulmonary disease 2013
Treeprasertsuk et al. The predictors of the presence of varices in patients with primary sclerosing cholangitis
CN110257518A (zh) 一种用于预测转移性结直肠癌转化治疗疗效的基因集
Nafady et al. Clinical Significance of miRNA-145 and-126 in Chronic Obstructive Pulmonary Disease with Pulmonary Embolism.
Giachero et al. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine
CN111808941A (zh) 一种与肺纤维化辅助诊断相关的外周血circRNA标志物及其应用
CN111471764B (zh) 一种用于筛查或辅助诊断胃癌的生物标志物组合及其试剂盒和应用
Swiss Association for the Study of the Liver Supplementum 272: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates
Tanrikulu et al. The value of new inflammatory parameters in malignant mesothelioma prognosis
Zhao et al. A novel disulfidptosis-related lncRNA signature to predict prognosis and immune response of cervical cancer